medigraphic.com
ISSN 2448-8909 (Print)

2017, Number 2

<< Back

Med Crit 2017; 31 (2)

Sudden cardiac arrest attributed to hypertrophic cardiomyopathy by use of anabolic steroids. Case report

Díaz CM, Brito MD, Márquez VFG, Hernández PRR

Language: Spanish
References: 17
Page: 101-105
PDF size: 235.80 Kb.


ABSTRACT

Hypertrophic cardiomyopathy is characterized by asymmetric and non-dilated left ventricle hypertrophy, sudden death is probably a consequence of unpredictable myocardial electrical disturbances that produce lethal arrhythmias. Cardiomyopathies are defined by the existence of structural and functional abnormalities of the left ventricle that can not be explained by coronary disease or abnormal load conditions causing the increased thickness of the wall of the left ventricle, within this diseases group exists genetic and nongenetic causes, these are described associated drugs including the use of anabolic androgenic steroids. Anabolic androgenic steroids are used to promote increased muscle mass, to improve the performance of athletes, this has led to the use and abuse of these products in professional and recreational athletes, chronic use in supraphysiological dose in this population is attaches a several cardiovascular manifestations as hypertrophic cardiomyopathy, this association between the use of anabolic androgenic steroids and cardiac hypertrophy has been shown in a study by pathological findings in ASS users deceased.1 The purpose of this communication is to report an unusual case in our hospital of a patient with chronic use of anabolic androgenic steroids and hypertrophic cardiomyopathy.


REFERENCES

  1. Far HR, Ågren G, Thiblin I. Cardiac hypertrophy in deceased users of anabolic androgenic steroids: an investigation of autopsy findings. Cardiovasc Pathol. 2012;21(4):312-316.

  2. Maisch B, Noutsias M, Ruppert V, Richter A, Pankuweit S. Cardiomyopathies: classification, diagnosis, and treatment. Heart Fail Clin. 2012;8(1):53-78.

  3. Maron BJ, Gohman TE, Aeppli D. Prevalence of sudden cardiac death during competitive sports activities in Minnesota high school athletes. J Am Coll Cardiol. 1998;32(7):1881-1884.

  4. Montisci M, El Mazloum R, Cecchetto G, Terranova C, Ferrara SD, Thiene G, et al. Anabolic androgenic steroids abuse and cardiac death in athletes: morphological and toxicological findings in four fatal cases. Forensic Sci Int. 2012;217(1-3):e13-e18.

  5. Lusetti M, Licata M, Silingardi E, Reggiani-Bonetti L, Palmiere C. Pathological changes in anabolic androgenic steroid users. J Forensic Leg Med. 2015;33:101-104.

  6. Evans NA. Current concepts in anabolic-androgenic steroids. Am J Sports Med. 2004;32(2):534-542.

  7. van Amsterdam J, Opperhuizen A, Hartgens F. Adverse health effects of anabolic-androgenic steroids. Regul Toxicol Pharmacol. 2010;57(1):117-123.

  8. Lichtenfeld J, Deal BJ, Crawford S. Sudden cardiac arrest following ventricular fibrillation attributed to anabolic steroid use in an adolescent. Cardiol Young. 2016;26(5):996-998.

  9. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122.

  10. Barrientos-Pérez M. Uso de anabólicos por atletas adolecentes. Rev Endocrinol Nutr. 2001;9(3):133-140.

  11. Aguila F, Mercado A, Palma C. Esteroides androgénicos anabolizantes: consecuencias en el hombre. Revista Chilena de Urología. 2013;78(4):13-17.

  12. Suárez-Mier M. Anabolizantes. Complicaciones cardiovasculares. Muerte súbita e inesperada. Cuad Med Forense. 2001;26:29-39.

  13. Fanton L, Belhani D, Vaillant F, Tabib A, Gomez L, Descotes J, et al. Heart lesions associated with anabolic steroid abuse: comparison of post-mortem findings in athletes and norethandrolone-induced lesions in rabbits. Exp Toxicol Pathol. 2009;61(4):317-323.

  14. Maron BJ. Sudden death in young athletes. N Engl J Med. 2003;349(11):1064-1075.

  15. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. Guía de práctica clínica de la ESC 2014 sobre el diagnóstico y manejo de la miocardiopatía hipertrófica. Rev Esp Cardiol. 2015;68(1):63.e1-e52.

  16. D’Andrea A, Limongelli G, Morello A, Mattera-Iacono A, Russo MG, Bossone E et al. Anabolic-androgenic steroids and athlete’s heart: When big is not beautiful....! Int J Cardiol. 2016;203:486-488.

  17. Bagatell CJ, Bremner WJ. Androgens in men--uses and abuses. N Engl J Med. 1996;334(11):707-714.




2020     |     www.medigraphic.com